Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Sierra Oncology to hold a conference call » 09:25
12/16/20
12/16
09:25
12/16/20
09:25
SRRA

Sierra Oncology

$15.10 /

-0.22 (-1.44%)

Chief Development Officer…

Chief Development Officer Klencke, along with Dr. Kiladjian of Saint-Louis Hospital, Dr. Mesa, Director of the Mays Cancer Center and Dr. Verstovsek of the MD Anderson Cancer center provide an overview of the Momelotinib data presented at the recently held ASH Annual Meeting on December 16 at 10 am. Webcast Link

ShowHide Related Items >><<
SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

12/11/20 H.C. Wainwright
Sierra Oncology assumed with a Buy at H.C. Wainwright
07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

Conference/Events
Sierra Oncology to hold a conference call » 04:55
12/16/20
12/16
04:55
12/16/20
04:55
SRRA

Sierra Oncology

$15.10 /

-0.22 (-1.44%)

Chief Development Officer…

Chief Development Officer Klencke, along with Dr. Kiladjian of Saint-Louis Hospital, Dr. Mesa, Director of the Mays Cancer Center and Dr. Verstovsek of the MD Anderson Cancer center provide an overview of the Momelotinib data presented at the recently held ASH Annual Meeting on December 16 at 10 am. Webcast Link

ShowHide Related Items >><<
SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

12/11/20 H.C. Wainwright
Sierra Oncology assumed with a Buy at H.C. Wainwright
07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

SRRA Sierra Oncology
$15.10 /

-0.22 (-1.44%)

Initiation
Sierra Oncology assumed with a Buy at H.C. Wainwright » 06:10
12/11/20
12/11
06:10
12/11/20
06:10
SRRA

Sierra Oncology

$15.08 /

-0.125 (-0.82%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis assumed coverage of Sierra Oncology with a Buy rating and $29 price target. Sierra is in a strong position to deliver a differentiated drug for the treatment of myelofibrosis with a projected launch in 2023, Pantginis tells investors in a research note.

ShowHide Related Items >><<
SRRA Sierra Oncology
$15.08 /

-0.125 (-0.82%)

SRRA Sierra Oncology
$15.08 /

-0.125 (-0.82%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$15.08 /

-0.125 (-0.82%)

SRRA Sierra Oncology
$15.08 /

-0.125 (-0.82%)

Conference/Events
Sierra Oncology to hold a conference call » 15:56
12/09/20
12/09
15:56
12/09/20
15:56
SRRA

Sierra Oncology

$15.20 /

+ (+0.00%)

Chief Development Officer…

Chief Development Officer Klencke, along with Dr. Kiladjian of Saint-Louis Hospital, Dr. Mesa, Director of the Mays Cancer Center and Dr. Verstovsek of the MD Anderson Cancer center provide an overview of the Momelotinib data presented at the recently held ASH Annual Meeting on December 16 at 10 am. Webcast Link

ShowHide Related Items >><<
SRRA Sierra Oncology
$15.20 /

+ (+0.00%)

SRRA Sierra Oncology
$15.20 /

+ (+0.00%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$15.20 /

+ (+0.00%)

SRRA Sierra Oncology
$15.20 /

+ (+0.00%)

Hot Stocks
Sierra Oncology reports retrospective analyses of Phase 3 SIMPLIFY studies » 10:16
12/07/20
12/07
10:16
12/07/20
10:16
SRRA

Sierra Oncology

$14.05 /

+ (+0.00%)

Sierra Oncology reported…

Sierra Oncology reported an updated efficacy analyses of momelotinib in myelofibrosis patients with thrombocytopenia. The data were presented in a poster presentation at the 2020 American Society of Hematology, or ASH, Annual Meeting by Jean-Jacques Kiladjian, MD, PhD, Consultant Hematologist, Head, Clinical Investigation Center, Saint Louis Hospital, Paris, France. "These exciting data provide a novel insight into a patient population where momelotinib's unique receptor inhibition profile-JAK1, JAK2 & ACVR1-may be particularly relevant. The observation of preserved activity in patients with reduced platelet counts is provocative and potentially differentiating. The wealth of information contained in the SIMPLIFY studies will enable further analyses and potentially identify additional populations of interest to be presented at future scientific meetings. We now look forward to completing enrollment in the pivotal Phase 3 MOMENTUM study and subsequent topline data to support our plan to file for regulatory approval of momelotinib for the treatment of myelofibrosis," said Stephen Dilly, MBBS, PhD, CEO at Sierra Oncology.

ShowHide Related Items >><<
SRRA Sierra Oncology
$14.05 /

+ (+0.00%)

SRRA Sierra Oncology
$14.05 /

+ (+0.00%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$14.05 /

+ (+0.00%)

SRRA Sierra Oncology
$14.05 /

+ (+0.00%)

Hot Stocks
Sierra Oncology presents long-term Overall Survival for momelotinib » 10:41
12/06/20
12/06
10:41
12/06/20
10:41
SRRA

Sierra Oncology

$14.05 /

+0.1 (+0.72%)

Sierra Oncology reported…

Sierra Oncology reported updated overall survival data for momelotinib in both JAKi-naive and patients previously treated with ruxolitinib. The data were presented in an oral presentation at the 2020 American Society of Hematology Annual Meeting. The SIMPLIFY-1 and SIMPLIFY-2 Phase 3 studies evaluated momelotinib against ruxolitinib or best available therapy for a 24-week randomization treatment phase, followed by an opportunity for extended momelotinib treatment for all patients. Robust OS was observed in both JAKi-naive and previously ruxolitinib-treated patients. In S1, the median OS has not been reached in the MMB arm and 53.1 months in the control arm. In S2, the median OS was 34.3 months in originally MMB-randomized patients and 37.5 months in the BAT/RUXaMMB arm, representing the best reported OS in this previously RUX-treated setting. Sustained transfusion independence was observed with extended MMB treatment. In S1, TI response at Week 24 was 67% in the MMB arm and 49% in the control arm. 40% of MMB-treated patients achieved a splenic response at any time during S1. The median duration of TI has not been reached after greater than3 years of follow up. In S2, TI response at Week 24 was 43% in the MMB arm and 21% in the control arm. Compound safety was favorable for MMB with limited hematological toxicity and lack of cumulative toxicity. Patients were randomized 1:1 and 2:1 to receive MMB versus RUX or BAT for 24 weeks followed by extended momelotinib treatment. Both trials had primary endpoints of Splenic Response Rate and secondary endpoints of Total Symptom Score and Transfusion Independence Rate.

ShowHide Related Items >><<
SRRA Sierra Oncology
$14.05 /

+0.1 (+0.72%)

SRRA Sierra Oncology
$14.05 /

+0.1 (+0.72%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
SRRA Sierra Oncology
$14.05 /

+0.1 (+0.72%)

SRRA Sierra Oncology
$14.05 /

+0.1 (+0.72%)

Earnings
Sierra Oncology reports Q3 EPS ($1.39), consensus ($1.64) » 08:00
11/05/20
11/05
08:00
11/05/20
08:00
SRRA

Sierra Oncology

$13.46 /

-0.34 (-2.46%)

Reports Q3 revenue $100K…

Reports Q3 revenue $100K vs. $0 a year ago. "We continue to make good progress in our pivotal MOMENTUM Phase 3 trial for momelotinib and anticipate completing target enrollment by approximately mid-2021 and reporting top-line data in H1 2022, subject to any unforeseen impact from COVID-19," said CEO Stephen Dilly. "In addition, we anticipate presenting new analyses from previously completed Phase 3 studies of momelotinib at the American Society of Hematology annual meeting in December 2020. We are also developing our internal capabilities to support potential future regulatory filings and commercialization of momelotinib in the U.S., with key hires made recently in Regulatory Affairs, Technical Operations, Legal, Pharmacovigilance, Commercial, Business Development and Medical Affairs. We remain well capitalized to complete enrollment for the MOMENTUM trial, report top-line results and to prepare for filing and pre-commercialization."

ShowHide Related Items >><<
SRRA Sierra Oncology
$13.46 /

-0.34 (-2.46%)

SRRA Sierra Oncology
$13.46 /

-0.34 (-2.46%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
SRRA Sierra Oncology
$13.46 /

-0.34 (-2.46%)

SRRA Sierra Oncology
$13.46 /

-0.34 (-2.46%)

Over a quarter ago
Hot Stocks
Sierra Oncology names Kevin Norrett as Chief Business Officer » 08:22
08/06/20
08/06
08:22
08/06/20
08:22
SRRA

Sierra Oncology

$11.72 /

-0.305 (-2.54%)

Sierra Oncology announced…

Sierra Oncology announced the appointments of Kevin Norrett as Chief Business Officer and William Turner as Chief Regulatory and Technical Operations Officer. Most recently, Kevin was Chief Commercial Officer at Angion Biomedica, a clinical stage company with a focus in acute organ injury and fibrosis. Turner was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years.

ShowHide Related Items >><<
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

Earnings
Sierra Oncology reports Q2 EPS ($1.58), consensus ($1.63) » 08:05
08/06/20
08/06
08:05
08/06/20
08:05
SRRA

Sierra Oncology

$11.72 /

-0.305 (-2.54%)

"We believe…

"We believe momelotinib, if approved, may provide an important treatment option for underserved myelofibrosis patients, in particular those with anemia and thrombocytopenia, and as such is well-positioned to generate significant value," said CEO Stephen Dilly. "During Q2, we continued to advance the MOMENTUM Phase 3 trial and are on track to deliver top-line results in the first half of 2022. In anticipation of these pivotal data, we are preparing for the regulatory submission process and the potential commercialization of momelotinib, and subsequent to the end of the quarter, we substantially strengthened our senior management team to support these activities". "We made significant progress during the first half of 2020 operationalizing the global MOMENTUM Phase 3 trial and, while the potential impact of the COVID-19 pandemic continues to be uncertain, we are pleased with the current pace of enrollment," said Barbara Klencke, Chief Development Officer. "During the EHA virtual conference, two world-leading physicians in the treatment of myelofibrosis reported long-term data that continue to reinforce momelotinib's differentiated durability, safety and efficacy profile. We plan to report updated analyses in late 2020 comparing the symptomatic benefits of momelotinib to ruxolitinib from the SIMPLIFY-1 Phase 3 trial that will further emphasize momelotinib's differentiated and competitive profile."

ShowHide Related Items >><<
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

Initiation
Fly Intel: Top five analyst initiations » 10:14
07/30/20
07/30
10:14
07/30/20
10:14
SNE

Sony

$77.55 /

-0.81 (-1.03%)

, SRRA

Sierra Oncology

$12.50 /

+ (+0.00%)

, ARCT

Arcturus Therapeutics

$53.75 /

+0.71 (+1.34%)

, MSGE

MSG Entertainment

$72.01 /

-1.13 (-1.54%)

, MSGS

MSG Sports

$153.23 /

+4.095 (+2.75%)

, SFM

Sprouts Farmers Market

$26.67 /

-0.46 (-1.70%)

, WMT

Walmart

$129.49 /

-1.21 (-0.93%)

, COST

Costco

$324.22 /

-1.21 (-0.37%)

, TGT

Target

$122.89 /

-0.785 (-0.63%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sony (SNE) resumed with a Conviction Buy at Goldman Sachs. 2. Sierra Oncology (SRRA) initiated with a Buy at H.C. Wainwright. 3. Arcturus Therapeutics (ARCT) resumed with a Buy at Roth Capital. 4. MSG Entertainment (MSGE) was initiated with an Equal Weight at Morgan Stanley while MSG Sports (MSGS) was initiated with an Overweight. 5. Sprouts Farmers Market (SFM) was initiated with a Buy at MKM Partners, while Walmart (WMT) and Costco (COST) were initiated with a Neutral and Target (TGT) was initiated with a Sell. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WMT Walmart
$129.49 /

-1.21 (-0.93%)

TGT Target
$122.89 /

-0.785 (-0.63%)

SRRA Sierra Oncology
$12.50 /

+ (+0.00%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

SFM Sprouts Farmers Market
$26.67 /

-0.46 (-1.70%)

MSGE MSG Entertainment
$72.01 /

-1.13 (-1.54%)

COST Costco
$324.22 /

-1.21 (-0.37%)

ARCT Arcturus Therapeutics
$53.75 /

+0.71 (+1.34%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

07/29/20 Goldman Sachs
Sony resumed with a Conviction Buy at Goldman Sachs
07/16/20 Guggenheim
Best Buy price target raised to $100 from $90 at Guggenheim
07/07/20 Loop Capital
Logitech price target raised to $78 from $58 at Loop Capital
06/12/20 MKM Partners
Take-Two upgraded to Buy after GTA V remaster announcement at MKM Partners
SRRA Sierra Oncology
$12.50 /

+ (+0.00%)

07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
ARCT Arcturus Therapeutics
$53.75 /

+0.71 (+1.34%)

07/30/20 Roth Capital
Arcturus Therapeutics resumed with a Buy at Roth Capital
07/24/20 H.C. Wainwright
Arcturus Therapeutics price target raised to $78 from $62 at H.C. Wainwright
07/16/20 Raymond James
Arcturus Therapeutics initiated with an Outperform at Raymond James
07/13/20 B. Riley Securities
B. Riley FBR starts Arcturus Therapeutics with Buy, $70 price target
MSGE MSG Entertainment
$72.01 /

-1.13 (-1.54%)

07/30/20 Morgan Stanley
MSG Entertainment initiated with an Equal Weight at Morgan Stanley
06/29/20 Jefferies
MSG Entertainment initiated with a Buy at Jefferies
06/25/20 Wolfe Research
MSG Entertainment initiated with an Outperform at Wolfe Research
06/17/20
Fly Intel: Top five analyst initiations
MSGS MSG Sports
$153.23 /

+4.095 (+2.75%)

07/30/20 Morgan Stanley
MSG Sports initiated with an Overweight at Morgan Stanley
06/25/20 Wolfe Research
MSG Sports initiated with an Outperform at Wolfe Research
06/17/20 Guggenheim
MSG Sports price target raised to $221 from $216 at Guggenheim
05/19/20 Evercore ISI
MSG Sports initiated with an Outperform at Evercore ISI
SFM Sprouts Farmers Market
$26.67 /

-0.46 (-1.70%)

07/30/20 MKM Partners
Sprouts Farmers Market initiated with a Buy at MKM Partners
07/29/20 MKM Partners
Sprouts Farmers Market initiated with a Buy at MKM Partners
07/21/20 Goldman Sachs
Sprouts Farmers Market initiated with a Neutral at Goldman Sachs
07/08/20 Barclays
Sprouts Farmers Market downgraded to Underweight from Equal Weight at Barclays
WMT Walmart
$129.49 /

-1.21 (-0.93%)

07/30/20 MKM Partners
BJ's Wholesale initiated with a Sell at MKM Partners
07/30/20 MKM Partners
Target initiated with a Sell at MKM Partners
07/30/20 MKM Partners
Costco initiated with a Neutral at MKM Partners
07/30/20 MKM Partners
Walmart initiated with a Neutral at MKM Partners
COST Costco
$324.22 /

-1.21 (-0.37%)

07/29/20 MKM Partners
Costco initiated with a Neutral at MKM Partners
07/13/20
Fly Intel: Top five analyst initiations
TGT Target
$122.89 /

-0.785 (-0.63%)

07/29/20 MKM Partners
Target initiated with a Sell at MKM Partners
07/12/20 Jefferies
Walmart/Target e-comm growth not seen coming at Amazon's expense, says Jefferies
06/24/20 B. Riley Securities
Hanesbrands products largely sold out at Walmart and Target, says B. Riley FBR
WMT Walmart
$129.49 /

-1.21 (-0.93%)

TGT Target
$122.89 /

-0.785 (-0.63%)

SRRA Sierra Oncology
$12.50 /

+ (+0.00%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

SFM Sprouts Farmers Market
$26.67 /

-0.46 (-1.70%)

COST Costco
$324.22 /

-1.21 (-0.37%)

ARCT Arcturus Therapeutics
$53.75 /

+0.71 (+1.34%)

  • 29
    Jul
  • 16
    Apr
WMT Walmart
$129.49 /

-1.21 (-0.93%)

TGT Target
$122.89 /

-0.785 (-0.63%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

MSGE MSG Entertainment
$72.01 /

-1.13 (-1.54%)

COST Costco
$324.22 /

-1.21 (-0.37%)

ARCT Arcturus Therapeutics
$53.75 /

+0.71 (+1.34%)

WMT Walmart
$129.49 /

-1.21 (-0.93%)

TGT Target
$122.89 /

-0.785 (-0.63%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

SFM Sprouts Farmers Market
$26.67 /

-0.46 (-1.70%)

COST Costco
$324.22 /

-1.21 (-0.37%)

ARCT Arcturus Therapeutics
$53.75 /

+0.71 (+1.34%)

WMT Walmart
$129.49 /

-1.21 (-0.93%)

TGT Target
$122.89 /

-0.785 (-0.63%)

SRRA Sierra Oncology
$12.50 /

+ (+0.00%)

SNE Sony
$77.55 /

-0.81 (-1.03%)

SFM Sprouts Farmers Market
$26.67 /

-0.46 (-1.70%)

MSGS MSG Sports
$153.23 /

+4.095 (+2.75%)

MSGE MSG Entertainment
$72.01 /

-1.13 (-1.54%)

COST Costco
$324.22 /

-1.21 (-0.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.